McGuire W L, Tandon A K, Allred D C, Chamness G C, Ravdin P M, Clark G M
Department of Medicine/Oncology, University of Texas Health Science Center, San Antonio 78284-7884.
Cancer. 1992 Sep 15;70(6 Suppl):1775-81. doi: 10.1002/1097-0142(19920915)70:4+<1775::aid-cncr2820701619>3.0.co;2-8.
Every month, treatment decisions must be made for more than 6000 patients with breast cancer without axillary node involvement in the United States. Approximately 70% of these patients will survive more than 10 years after surgery and/or radiation treatment without additional systemic adjuvant therapy. If we had good methods to identify patients who are destined to have a recurrence of their disease, only those patients should receive adjuvant therapy.
The authors reviewed the literature supporting the use of currently available prognostic factors for patients with node-negative breast cancer, and formulated a framework on which prognostic factor information can be based to help make these treatment decisions.
The steps involved in making treatment decisions are: use prognostic factors to determine the recurrence probability; calculate the expected treatment benefit; and weigh the expected benefits against the potential risks.
Prognostic factors can be used to help make treatment decisions for patients with breast cancer without axillary node involvement. However, the final treatment decision must take into account all aspects of the patient and her disease, and the physician must help the patient evaluate her prognostic factors, arrive at an understanding of her particular risk of recurrence, and weigh the potential benefits and risks of adjuvant therapy.
在美国,每月必须为6000多名无腋窝淋巴结转移的乳腺癌患者做出治疗决策。这些患者中约70%在接受手术和/或放射治疗后,无需额外的全身辅助治疗即可存活超过10年。如果我们有好的方法来识别注定会疾病复发的患者,那么只有这些患者才应接受辅助治疗。
作者回顾了支持对无淋巴结转移乳腺癌患者使用现有预后因素的文献,并制定了一个框架,预后因素信息可基于此框架来帮助做出这些治疗决策。
做出治疗决策所涉及的步骤为:使用预后因素确定复发概率;计算预期治疗获益;权衡预期获益与潜在风险。
预后因素可用于帮助为无腋窝淋巴结转移的乳腺癌患者做出治疗决策。然而,最终的治疗决策必须考虑患者及其疾病的所有方面,医生必须帮助患者评估其预后因素,了解其特定的复发风险,并权衡辅助治疗的潜在获益和风险。